The GI-4000 therapeutic vaccine or placebo will be injected under the skin of post-resection, non-metastatic pancreas cancer patients. Patients will be monitored for recurrence as well as safety, and immune responses related to the injections.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
176
Heat-killed yeast cell transfected with target ras mutation.
Chemotherapy
Recurrence free time and survival
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Tower Cancer Research Foundation
Beverly Hills, California, United States
University of California San Diego
La Jolla, California, United States
UCLA Medical Center
Los Angeles, California, United States
Georgetown University Medical Center / Lombardi Cancer Center
Washington D.C., District of Columbia, United States
Rush University Medical School
Chicago, Illinois, United States
Minnesota Oncology Hematology, PA
Minneapolis, Minnesota, United States
Washington University
St Louis, Missouri, United States
State University of NY at Stony Brook
Stony Brook, New York, United States
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
...and 18 more locations